<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01535443</url>
  </required_header>
  <id_info>
    <org_study_id>BRON0611V1FI</org_study_id>
    <nct_id>NCT01535443</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of PRO-155 Ophthalmic Solution 0.09% in Healthy Volunteers.</brief_title>
  <acronym>PRO-155</acronym>
  <official_title>STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PRO-155 OPHTHALMIC SOLUTION 0.09% IN HEALTHY VOLUNTEERS.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Sophia S.A de C.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorios Sophia S.A de C.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to evaluate the safety and tolerability of PRO-155 Ophthalmic Solution 0.09 % in
      healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase I, open label and unicentric clinical trial to evaluate the safety and tolerability
      of PRO-155 Ophthalmic Solution 0.09 % in healthy volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of PRO-155 Ophthalmic Solution</measure>
    <time_frame>10 days</time_frame>
    <description>Evaluating of ocular signs and symptoms,visual acuity (VA), biomicroscopy, intraocular pressure (IOP), funduscopy and cup disc-ratio.
Evualuating the corneal and interpalpebral conjunctival staining (Fluoroscein and lissamine green staining).
Frequency, severity and relationship to study medication of all adverse events occurring during the course of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability of PRO-155 Ophthalmic Solution.</measure>
    <time_frame>10 days</time_frame>
    <description>- Evaluating of ocular symptoms (redness eye, burning, foreign body sensation,photophobia and tearing) and ocular signs (hyperemia conjunctiva).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Ocular Inflammation</condition>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>PRO-155 Ophthalmic Solution 0.09 %</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRO-155 Ophthalmic Solution 0.09 %</intervention_name>
    <description>PRO-155 Ophthalmic Solution 0.09 % applied twice to day during 10 days..</description>
    <arm_group_label>PRO-155 Ophthalmic Solution 0.09 %</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female.

          -  Age ≥ 18 years old at screening visit

        Exclusion Criteria:

          -  Any ocular or systemic condition.

          -  Patient with one blind eye.

          -  Visual acuity of 20/40 in any eye.

          -  Use of ocular or systemics medications.

          -  Contraindications or sensitivity to any component of the study treatments.

          -  Contact lens users.

          -  Ocular surgery within the past 3 months..

          -  Women who were not using an effective means of contraception or who were pregnant or
             nursing.

          -  Participation in any studies of investigational drugs within 90 days previous to the
             inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alfredo Lizarraga-Corona, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unidad Medica &quot;Grupo Pediátrico&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leopoldo M Baiza-Duran, MD</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Research Department. Laboratorios Sophia SA de CV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unidad Medica &quot;Grupo Pediátrico&quot;</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44690</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2012</study_first_submitted>
  <study_first_submitted_qc>February 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2012</study_first_posted>
  <last_update_submitted>February 24, 2012</last_update_submitted>
  <last_update_submitted_qc>February 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PRO-155</keyword>
  <keyword>Ocular NSAIDs</keyword>
  <keyword>Safety and tolerability</keyword>
  <keyword>Ocular Inflammation</keyword>
  <keyword>Ocular Paint</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>June 3, 2013</submitted>
    <returned>August 19, 2013</returned>
    <submitted>August 29, 2013</submitted>
    <returned>November 4, 2013</returned>
    <submitted>November 6, 2013</submitted>
    <returned>December 27, 2013</returned>
    <submitted>May 19, 2014</submitted>
    <returned>June 14, 2014</returned>
    <submitted>June 8, 2017</submitted>
    <returned>February 1, 2018</returned>
    <submitted>February 8, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

